Key words: Expert Council, antibacterial therapy, antimicrobial resistance, community-acquired infections, respiratory tract infections, respiratory infections, amoxicillin-clavulanate, high-dose therapy, children.
About the AuthorRoman S. Kozlov 1 , Alexander I. Sinopalnikov 2 , Olga V. Zaitseva 3 , Sergey K. Zyryanov 4 5 , Elena P. Karpova 2 , Elena Yu. Radzig 6 , Svetlana V. Zaitseva 3 , Evelina E. Lokshina 3 , Olga U. Stetsyuk 1 , Irina V. Andreeva 1
1 Smolensk State Medical University of the Ministry of Health of the Russian Federation, Smolensk, Russia
2 Russian Medical Academy of Continuous Professional Education, Moscow, Russia
3 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
4 The Peoples' Friendship University of Russia, Moscow, Russia
5 City Clinical Hospital 24 DZM, Moscow, Russia
6 Pirogov Russian National Research Medical University, Moscow, Russia
For citation:Kozlov R.S., Sinopalnikov A.I., Zaitseva O.V., Zyryanov S.K., Karpova E.P., Radzig E.Yu., Zaitseva S.V., Lokshina E.E., Stetsyuk O.U., Andreeva I.V. Inhibitor-protected amoxicillin with increased amoxicillin content and active ingredients ratio of 14:1: the use for treatment of community-acquired respiratory infections and ENT infections in children. Expert Council Resolution. Clinical review for general practice. 2021; 2: 6–14. DOI: 10.47407/kr2021.2.1.00036
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.